Trial Profile
Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Aspirin
- Indications Acute coronary syndromes; Angina pectoris; Ischaemia; Ischaemic heart disorders; Myocardial infarction; Stroke; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRASFIT-Practice II
- Sponsors Daiichi Sankyo Company
- 02 Oct 2020 Final two-year follow-up results published in the Circulation Journal.
- 12 Nov 2019 Results of one year follow up study assessing effectiveness and safety of prasugrel were published in the Circulation Journal
- 24 Jan 2019 Results of interim analysis of data from case report forms (CRFs) after 3 months published in the Circulation Journal